Capricor Therapeutics (CAPR) Cash from Investing Activities (2011 - 2026)

Capricor Therapeutics' Cash from Investing Activities history runs 15 years deep, the most recent figure standing at -$154.6 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 747.29% year-over-year to -$154.6 million; the TTM figure through Mar 2026 stood at -$81.1 million (up 2.1% YoY), while the FY2025 annual figure was $97.5 million, up 183.9% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$154.6 million, down from $43.1 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $43.1 million in Q4 2025, with the low at -$154.6 million in Q1 2026.
• The 5-year median for Cash from Investing Activities is $2.0 million (2024), against an average of -$12.0 million.
• Peak annual rise in Cash from Investing Activities reached 1494.77% in 2022, while the deepest fall reached 10882.05% in 2022.
• Capricor Therapeutics' Cash from Investing Activities stood at $5.1 million in 2022, then plunged by 214.01% to -$5.9 million in 2023, then tumbled by 2004.53% to -$123.4 million in 2024, then jumped by 134.92% to $43.1 million in 2025, then slumped by 458.89% to -$154.6 million in 2026.
• Business Quant data shows CAPR's Cash from Investing Activities at -$154.6 million in Q1 2026, $43.1 million in Q4 2025, and $16.0 million in Q3 2025.